SEATTLE, March 27, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the upcoming presentation of recent research in precision oncology and predictive biomarkers using the nCounter® Analysis System. More than 45 NanoString-related abstracts will be presented at the Annual Meeting of the American Association of Cancer Research (AACR), which is being held April 1-5, 2017, in Washington, DC.
"We are proud to see our products and technologies being used so broadly to advance the understanding of cancer. We salute these researchers and the groundbreaking contributions to cancer research that are being presented at the 2017 Annual Meeting of the AACR,” said Brad Gray, president and chief executive officer of NanoString Technologies. “Our nCounter technology has become an essential tool for biomarker research, and we continue to expand the capabilities and content to drive adoption in other areas of research such as autoimmune syndromes, infectious disease and neurology.”
The 2017 AACR abstracts describe research applications that underscore the diverse capabilities and robust performance of the nCounter platform. These studies cover a wide range of cancers, tissue types (FFPE, peripheral blood and urine), and treatment modalities. There are at least 33 abstracts authored by academic researchers and 13 by biopharma researchers. These abstracts span translational research from biomarker validation and disease characterization, to drug resistance and autoimmune toxicities of checkpoint inhibitors.
NanoString will be exhibiting at AACR (booth# 3115) and hosting a workshop entitled “Powering Precision Oncology Research with 3D Biology Technology: High Plex Multi-Analyte Profiling on FFPE with Spatial Resolution” at 10:00am ET on Monday April 3.
| Abstract # | Title | Hyperlink |
| 471/12 | HER2 regulates PARP-1 expression by suppressing the let-7a microRNA in HER2+ breast cancer | http://www.abstractsonline.com/pp8/#!/4292/presentation/2057 |
| 414/14 | Identifying selective vulnerabilities in colorectal cancer molecular subtypes using in vivo functional genomic screens | http://www.abstractsonline.com/pp8/#!/4292/presentation/6665 |
| 811/17 | Histological heterogeneity contributes to sunitinib resistance in clear cell renal cell carcinoma | http://www.abstractsonline.com/pp8/#!/4292/presentation/1784 |
| 588/22 | Advanced molecular characterization of severe autoimmune toxicities associated with checkpoint inhibitor therapies | http://www.abstractsonline.com/pp8/#!/4292/presentation/6096 |
| 491/5 | Elucidating de novo PATRR-mediated t(3;8) balanced translocation and clear cell renal cell carcinoma | http://www.abstractsonline.com/pp8/#!/4292/presentation/1159 |
| 829/7 | MicroRNA regulation of radiation sensitivity in colorectal cancer | http://www.abstractsonline.com/pp8/#!/4292/presentation/2397 |
| 1682/1 | Correlation of immune co-stimulatory molecule OX40 and outcome in trastuzumab treated HER2-positive breast cancer patients in the NCCTG-N9831. | http://www.abstractsonline.com/pp8/#!/4292/presentation/5987 |
| 1750/10 | Analysis of non-metastatic HCC patient tumors revealed the significance of cell cycle regulation and tumor immunity in association with overall survival and identified clinically relevant druggable targets | http://www.abstractsonline.com/pp8/#!/4292/presentation/2931 |
| 1469/11 | Integrated analysis of microRNA, mRNA, and protein expression utilizing MultiOmyx and NanoString from formalin-fixed paraffin-embedded, lung, head and neck, breast, and melanoma tumors | http://www.abstractsonline.com/pp8/#!/4292/presentation/2080 |
| 1785/15 | Technical validation of novel 325 RNA predictive biomarkers using gene expression data generated by Nanostring n-counter and Affymetrix microarray | http://www.abstractsonline.com/pp8/#!/4292/presentation/1589 |
| 1904/5 | Novel 5-fluorouracil-thymoquinone hybrid kills colon cancer stem cells | http://www.abstractsonline.com/pp8/#!/4292/presentation/5919 |
| 2088/15 | The activity of the FGFR selective inhibitor Debio 1347 is correlated with high mRNA expression | http://www.abstractsonline.com/pp8/#!/4292/presentation/3926 |
| 2841/14 | Investigating drivers of disease progression in invasive lobular carcinoma | http://www.abstractsonline.com/pp8/#!/4292/presentation/3513 |
| 2441/28 | NanoString 3D Biology technology: simultaneous digital counting of DNA, RNA and protein | http://www.abstractsonline.com/pp8/#!/4292/presentation/6870 |
| 2251/5 | Tumor tissue gene expression in association with survival of triple-negative breast cancer | http://www.abstractsonline.com/pp8/#!/4292/presentation/2562 |
| 2422/9 | Simultaneous detection of activating somatic DNA mutations and expressed fusion transcripts from lung tumor FFPE samples | http://www.abstractsonline.com/pp8/#!/4292/presentation/6827 |
| 3814/10 | A pan cancer analysis of the tumor inflammation signature | http://www.abstractsonline.com/pp8/#!/4292/presentation/1652 |
| 3612/11 | Combination FGFR4 and ER-targeted therapy for invasive lobular carcinoma | http://www.abstractsonline.com/pp8/#!/4292/presentation/2276 |
| 3431/11 | The oncogenic role of miR-150-5p in triple-negative breast cancer | http://www.abstractsonline.com/pp8/#!/4292/presentation/2127 |
| 3706/19 | Validation of human and mouse myeloid panels on the NanoString nCounter Platform | http://www.abstractsonline.com/pp8/#!/4292/presentation/3240 |
| 3738/23 | Use of tumor mRNA expression for patient selection in a phase I study of the pan-fibroblast growth factor receptor inhibitor BAY 1163877 | http://www.abstractsonline.com/pp8/#!/4292/presentation/3003 |
| 3955/22 | Spatially resolved, multiplexed digital characterization of protein and mRNA distribution and abundance in formalin-fixed, paraffin-embedded (FFPE) tissue sections based on NanoString’s Digital Spatial Profiling (DSP) technology: applications to immuno-oncology (IO) and tumor heterogeneity | http://www.abstractsonline.com/pp8/#!/4292/presentation/3416 |
| 3652/25 | Combinational activity of LAG3 and PD-1 targeted therapies is significantly enhanced by the addition of phosphatidylserine targeting antibodies and establishes an anti-tumor memory response in murine triple negative breast cancer | http://www.abstractsonline.com/pp8/#!/4292/presentation/6260 |
| 3983/26 | A cross comparison of technologies for the detection of immune system related gene expression signatures in clinical FFPE samples of metastatic prostate cancer patients | http://www.abstractsonline.com/pp8/#!/4292/presentation/9068 |
| 3684/27 | Inhibition of STAT3 by antisense oligonucleotide treatment decreases the immune suppressive tumor microenvironment in syngeneic and GEM tumor models | http://www.abstractsonline.com/pp8/#!/4292/presentation/6345 |
| 3423/3 | Elucidation of the role of miR-575 on tumorigenesis in glioblastoma | http://www.abstractsonline.com/pp8/#!/4292/presentation/2119 |
| 3810/6 | Validation of novel high-plex protein spatial profiling quantitation based on NanoString's Digital Spatial Profiling (DSP) technology with quantitative fluorescence (QIF) | http://www.abstractsonline.com/pp8/#!/4292/presentation/1648 |
| 3377/8 | Simultaneous analysis of the mutational landscape and RNA and protein expression profile of HER2-positive breast cancer using 3D Biology | http://www.abstractsonline.com/pp8/#!/4292/presentation/6631 |
| NG04 | Mechanisms of resistance to anti-PD-1 immunotherapy through interferon pathway mutations | http://www.abstractsonline.com/pp8/#!/4292/presentation/11061 |
| 4649/10 | Development of an ethnicity informed gene expression panel with potential to improve prostate cancer diagnosis | http://www.abstractsonline.com/pp8/#!/4292/presentation/1628 |
| 4334/13 | Interleukin-6 is a key player in stroma-induced resistance to chemotherapy for gastric carcinomas | http://www.abstractsonline.com/pp8/#!/4292/presentation/5224 |
| 4387/19 | The clonal composition of colorectal cancer cell lines is defined by the maintenance of specific genomic imbalances, not by ongoing chromosomal instability | http://www.abstractsonline.com/pp8/#!/4292/presentation/6569 |
| 4197/20 | Interaction of B lymphoma cells with the microenvironment affects ibrutinib sensitivity | http://www.abstractsonline.com/pp8/#!/4292/presentation/3904 |
| 4442/20 | micoRNA in FA defective tumor | http://www.abstractsonline.com/pp8/#!/4292/presentation/2156 |
| 4262/28 | Inflammatory gene expression differences among prostate cancer patients exposed to the World Trade Center aftermath | http://www.abstractsonline.com/pp8/#!/4292/presentation/4794 |
| 4971 | IACS-010759, a novel inhibitor of complex I in Phase I clinical development to target OXPHOS dependent tumors | http://www.abstractsonline.com/pp8/#!/4292/presentation/3226 |
| 5000 | A stromal liver gene signature predictive of HCC risk across all liver disease etiologies | http://www.abstractsonline.com/pp8/#!/4292/presentation/7455 |
| 5095/11 | Development of a pharmacodynamic biomarker assay for AZD4785, an antisense oligonucleotide targeting KRAS | http://www.abstractsonline.com/pp8/#!/4292/presentation/2614 |
| 5448/13 | An exosomal biomarker for prostate cancer | http://www.abstractsonline.com/pp8/#!/4292/presentation/2172 |
| 5645/17 | Associations between biomarkers and outcome in a patient cohort with invasive lobular carcinoma | http://www.abstractsonline.com/pp8/#!/4292/presentation/993 |
| 5563/21 | 3D Biology view of cancer: Simultaneous detection of somatic DNA mutations and expression profiling of genes and signaling proteins from melanoma tumor FFPE samples | http://www.abstractsonline.com/pp8/#!/4292/presentation/1756 |
| 5726/20 | A novel tumor-promoting role for miR-4516 in glioblastoma | http://www.abstractsonline.com/pp8/#!/4292/presentation/1479 |
| 5757/21 | Study of human mammary tumor virus (HMTV) in human breast cancer by NanoString nCounter and FISH analysis | http://www.abstractsonline.com/pp8/#!/4292/presentation/2332 |
| 5652/6 | Translational evidence of reactivated innate and adaptive immunity with intratumoral IMO-2125 in combination with systemic checkpoint inhibitors from a Phase I/II study in patients with anti-PD-1 refractory metastatic melanoma | http://www.abstractsonline.com/pp8/#!/4292/presentation/6014 |
| 5350/6 | A comprehensive and integrated approach to genomic and proteomic analysis of FFPE NSCLC tumor specimens | http://www.abstractsonline.com/pp8/#!/4292/presentation/6724 |
| 5092/8 | ZVex lentiviral vector strongly activates pro-inflammatory, antigen processing, and antiviral defense response pathways in monocyte-derived dendritic cells | http://www.abstractsonline.com/pp8/#!/4292/presentation/2611 |
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1500 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.
For more information, please visit www.nanostring.com.
The NanoString Technologies logo, NanoString, NanoString Technologies, nCounter, 3D Biology, and Prosigna are registered trademarks or trademarks of NanoString Technologies, Inc. in various jurisdictions.
Contact: Doug Farrell Vice President, Investor Relations & Corporate Communications dfarrell@nanostring.com Phone: 206-602-1768
